Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tejas: Migaldendranib in wAMD and DME
NCT05387837Phase 2Active, not recruiting
- Start
- Aug 2022
- Primary completion
- May 2025
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dendranib in neovascular age-related macular degeneration (NVAMD) and diabetic macular edema (DME) (4 arms). Primary endpoints: Stage 1 Safety Evaluation at 12 weeks and Stage 1A Safety Evaluation at 40 weeks. Started Aug 2022; status: active, not recruiting.
02
Drugs
dendranib
03
Conditions
neovascular age-related macular degeneration (NVAMD)diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05387837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387837.